You are here

ReCode Therapeutics

ReCode Raises $260M in Series B Financing to Advance Lead Programs

BioSpace

Wed, 09/20/23 - 11:04 pm

ReCode Therapeutics

primary ciliary dyskinesia

cystic fibrosis

Spotlight – Cystic fibrosis developers take a deep breath

EP Vantage

Mon, 02/27/23 - 10:02 am

cystic fibrosis

Vertex Pharmaceuticals

4D Molecular Therapeutics

Arcturus Therapeutics

Arrowhead Pharmaceuticals

Boehringer Ingelheim

Eloxx Pharmaceuticals

Krystal Biotech

Moderna Therapeutics

Oxford BioMedica

ReCode Therapeutics

Sumitomo Pharmaceuticals

Tessera Therapeutics

The retrenchment begins for venture funding

EP Vantage

Fri, 07/8/22 - 10:36 am

venture capital

Frontera Therapeutics

Tessa Therapeutics

ReCode Therapeutics

ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs

MedCity News

Thu, 10/21/21 - 11:26 pm

ReCode Therapeutics

lipid nanoparticles

Coupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world

Endpoints

Thu, 03/26/20 - 10:31 am

ReCode Therapeutics

cystic fibrosis